Health Care & Life Sciences » Biotechnology | Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.94
Market Cap
$300.4 M
Shares Outstanding
23.4 M
Public Float
17.08 M

Profile

Address
7707 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.protagonist-inc.com
Updated 07/08/2019
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively.

Financials

View All
Created with Highcharts 5.0.14Protagonist Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.11 07211 07214 85814 85837 17737 17736 95736 95738 92438 92420142015201620172018010k20k30k40k50k
Created with Highcharts 5.0.14Protagonist Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.00000020 06320 06330 92530 92520142015201620172018010k20k30k40k

Dinesh V. Patel
President, CEO & Executive Director
Harold E. Selick
Chairman